Ms. Mann’s representative experience includes the following:
Strategic Alliances and Collaborations:
- Obsidian Therapeutics Inc. in its multiyear collaboration with Celgene Corporation to develop novel, regulated cell therapies for an upfront cash payment and an equity investment from Celgene for exclusive options to globally license the programs under the collaboration
- Kyn Therapeutics Inc. in its strategic collaboration with Celgene Corporation to develop novel immuno-oncology therapies for an upfront cash payment of $80 million and an equity investment from Celgene for exclusive options to globally license the Kynase and AHR antagonist programs
- Aegerion Pharmaceuticals, Inc. in its exclusive licensing agreement with Recordati Rare Diseases Inc. for the commercialization of JUXTAPID® (lomitapide) in Japan for a $25 million upfront payment, plus commercial milestones up to a total of $80 million and a royalty
Prior to joining Goodwin in 2018, Ms. Mann worked for approximately three years as Senior Manager & Associate Corporate Counsel in the Corporate Legal group at Vertex Pharmaceuticals Incorporated, where she managed intellectual property licensing and drafted and negotiated contracts for Vertex’s pharmaceutical operations, research and development, quality assurance and preclinical development. At Vertex, Ms. Mann led business development efforts with respect to a number of transactions, including the transaction described here: Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines. Ms. Mann’s in-house background provides her with a unique perspective on her clients’ legal needs.
Prior to Ms. Mann’s time at Vertex, she clerked for the Honorable Gregory I. Massing at the Massachusetts Court of Appeals.